The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...
It’s the first new pharmaceutical approach to treating pain in more than 20 years, offering an alternative to both opioids ...
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...
On a quiet Friday morning in Troy, Michigan, a tragic event unfolded at The Oxford Medical Center, leaving a community in shock. A hyperbaric chamber, which is typically used for medical treatments, ...